XML 20 R10.htm IDEA: XBRL DOCUMENT

License, Collaboration, and Funding Agreements	3 Months Ended
License, Collaboration, and Funding Agreements	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License, Collaboration, and Funding Agreements	LICENSE, COLLABORATION AND FUNDING AGREEMENTS Research and Development Incentive Program The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses and capital expenditures incurred by the Company’s subsidiary in Austria. As of March 31, 2022, the amount due under the program is $0.9 million, which amount was included in research and development incentive receivable in the condensed consolidated balance sheet. During the three months ended March 31, 2022 and 2021, the Company recorded $0.1 million and $0.3 million, respectively, of income related to the program within the condensed consolidated statements of operations as other income. License and Collaboration Agreements During the three months ended March 31, 2022, a third party, who had previously acquired rights to certain intellectual property from the Company, terminated the arrangement and transferred these rights back to the Company. Also during the three months ended March 31, 2022, the Company transferred these rights to another third party in return for $0.5 million. The Company has no continuing involvement in any ongoing research and development activities associated with the intellectual property. The Company concluded that these third parties are "non-customers" as the underlying intellectual property transferred to and from these third parties supports potential drug candidates that are not aligned with the Company's strategic focus and, therefore, are not an output of the Company's ordinary activities. Accordingly, the Company accounted for the sale of the intellectual property as the sale of a non-financial asset under ASC Topic 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets ("ASC 610-20"), and included the gain as part of gain on sale of non-financial asset for the period ended March 31, 2022. There were no material modifications of the Company’s license or collaboration agreements during the three months ended March 31, 2022.